H1PVAT

MedChemExpress

HY-12349		
351438-49-8	8	
C ₁₉ H ₁₄ F ₃ N ₅ C	S	
417.41		
Others		
Others		
Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month
	351438-49-4 C ₁₉ H ₁₄ F ₃ N ₅ C 417.41 Others Others Powder	$351438-49-8C_{19}H_{14}F_{3}N_{5}OS417.41OthersOthersPowder -20°C4°CIn solvent -80°C$

Product Data Sheet

N-N HN

≡N

BIOLOGICAL ACTIVITY			
Description	H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation ^{[1][2]} .		
IC ₅₀ & Target	EC50: 10 nM (PV-1), 26 nM (PV-2), 218 nM (PV-3) ^[1]		
In Vitro	 H1PVAT (10-218 nM; 24-48 h) inhibits poliovirus strain Sabin replication in a dose-dependent manner, with EC₅₀s of 10 nM (PV-1), 26 nM (PV-2) and 218 nM (PV-3), respectively^[1]. H1PVAT (30 min prior to or 1 h after PV-1 infection; 7 h) inhibits an early stage of viral replication , and only H1PVAT is administered prior to infection results reduction (>99.9%) in intracellular viral RNA levels^[1]. H1PVAT (50 μM; 2 min) protects PV against heat inactivation with the 50% thermal inactivation temperature increased to 52.6 🛛 and 50.8 🖾, which suggests a direct interaction between the viral capsid and H1PVAT^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 		

REFERENCES

[1]. Tijsma A, et al. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1. Antiviral Res. 2014 Oct;110:1-9.

[2]. Tijsma A. Antiviral strategies against polio and other enteroviruses. 2018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA